CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 3 enrolled
Drug / intervention
active tDCSdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05478681
NCT05478681N/ACompleted
CompareCT.gov

Home-based tDCS for Behavioral Symptoms in Alzheimer's Disease and Related Dementias (ADRD)

The University of Texas Health Science Center, Houston·interventional·Posted Jul 28, 2022·Updated Oct 10, 2025

In Brief

A clinical study evaluating active tDCS for Alzheimer Disease. Completed, enrolled 3 participants across 2 sites.

Detailed Summary

The purpose of this study is to assess acceptability, and safety of providing tDCS to ADRD patients with behavioral symptoms and to assess the efficacy of tDCS for ADRD-related symptoms, mainly behavioral symptoms.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAlzheimer Disease
CountriesUnited States
CollaboratorsTexas Alzheimer's Research and Care Consortium

Timeline

N/ACompletedFinished
2023202420252026
First PostedJul 28, 2022
Enrollment StartApr 17, 2023
Primary CompletionFeb 26, 2024
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 3.9 years ago

Interventions

active tDCSdevice

All participants will receive active tDCS with a constant current intensity of 2mA. Anodal tDCS will be applied to the left dorsolateral prefrontal cortex, while cathodal electrode will be positioned on the right dorsolateral prefrontal cortex. Caregivers will help setting up and administering tDCS for participants with AD at home. tDCS will be applied for 30min at an intensity of 2mA, with 30 s ramping up and down.